CommonHealth combines Ferguson, Noesis

Share this article:
CommonHealth president and CEO Matt Giegerich
CommonHealth president and CEO Matt Giegerich
CommonHealth is merging two of its professional agencies – Noesis and Ferguson.

Noesis, formerly based in Morristown, NJ, will move in with Ferguson at the WPP network's Parsippany, NJ,  campus. The combined agency will operate under the Ferguson flag and will boast a staff of around 130.

CommonHealth president and CEO Matt Giegerich stressed that the move was not a response to any loss of business and that there would be no redundancies in the merger. Quite the contrary, he said the network is on a hiring spree, looking to fill around 75 positions across all agencies, but that the merger is a response to the evolving business model of CommonHealth's clients.

“Having a decentralized organization makes less and less sense the way the business works today,” said Giegerich. “Clients are looking for integration. Their needs are for depth of talent and resources. The days of separate operating companies harmoniously coexisting doesn't make as much sense. So when we looked at our 2009 planning, we tortured the question of why we needed a fourth professional advertising agency. Now we'll have three independent groups with the right size and management team, and it gives us some conflict options.”

In addition to Ferguson, CommonHealth has Carbon and Altum handling professional marketing, along with EvoLogue, which offers DTC, CRM and strategic planning, and other units devoted to CME, media planning, managed markets and other specialties.

CommonHealth managing partner Dave Chapman said the agency will “elevate the role of strategic planning in pharma marketing to a higher level than ever before.”

“We're not just bringing the two groups together,” said Chapman. “It also gives us the chance to execute a new vision of how an agency should be structured in a world completely different to the one agencies were modeled after 30 years ago.”

The agency will be co-led by Ferguson president Chris Tama, who retains his title, and John Nosta, formerly president of Noesis, who becomes chief strategy officer at the combined shop.

The agency will handle primary care, specialty and OTC brands from clients including Johnson & Johnson, AstraZeneca, Bristol-Myers Squibb, Merck, GlaxoSmithKline and Barr.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...